Medical Therapy of Benign Prostatic Hyperplasia: A review

P* Maskey

Abstract


Medical treatment of benign prostatic hyperplasia (BPH) has conventionally been based on alpha blockers and 5-alpha reductase inhibitors. There has been a paradigm shift in this concept with the introduction of other agents. The treatment of BPH should be based not only on the size of prostate and severity of symptoms, but also on the type of symptoms (predominant storage versus obstructive), probability of progression, and the presence or absence of sexual dysfunction

Full Text:

VIEW PDF